Seoul, South Korea

Gihoon Nam

This inventor holds 1 USPTO granted patent. Top assignee: Shiftbio. Active years: 2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Gihoon Nam. Retrieved from https://idiyas.com/inventor/gihoon-nam

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Gihoon Nam: Innovator in Cancer Treatment

Introduction

Gihoon Nam is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of cancer treatment through his innovative research and development.

Latest Patents

Gihoon Nam holds a patent for a recombinant plasma membrane-based vesicle designed for treating cancer. This invention specifically involves a recombinant plasma membrane-based vesicle that includes a VSV-G mutated protein, where histidine at the 162nd amino acid position has been substituted with arginine. The patent also encompasses a pharmaceutical composition for treating cancer that utilizes this recombinant vesicle.

Career Highlights

Gihoon Nam is currently associated with Shiftbio, a company focused on advancing biotechnological solutions. His work at Shiftbio emphasizes the development of novel therapeutic approaches to combat cancer.

Collaborations

Some of his notable coworkers include In-San Kim and Gi-beom Kim, who contribute to the innovative environment at Shiftbio.

Conclusion

Gihoon Nam's work exemplifies the intersection of innovation and healthcare, particularly in the fight against cancer. His patented technology holds promise for future advancements in cancer treatment.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…